Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) Operating Income (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Operating Income for 7 consecutive years, with -$6.2 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Operating Income rose 58.08% year-over-year to -$6.2 million, compared with a TTM value of -$27.5 million through Dec 2019, up 55.02%, and an annual FY2024 reading of -$90.9 million, down 117.66% over the prior year.
  • Operating Income was -$6.2 million for Q4 2019 at Larimar Therapeutics, up from -$12.9 million in the prior quarter.
  • Across five years, Operating Income topped out at $4.8 million in Q2 2019 and bottomed at -$23.2 million in Q4 2015.
  • Average Operating Income over 5 years is -$13.7 million, with a median of -$14.1 million recorded in 2017.
  • The sharpest move saw Operating Income tumbled 194.19% in 2015, then surged 131.16% in 2019.
  • Year by year, Operating Income stood at -$23.2 million in 2015, then skyrocketed by 54.94% to -$10.5 million in 2016, then fell by 27.52% to -$13.4 million in 2017, then dropped by 9.98% to -$14.7 million in 2018, then soared by 58.08% to -$6.2 million in 2019.
  • Business Quant data shows Operating Income for LRMR at -$6.2 million in Q4 2019, -$12.9 million in Q3 2019, and $4.8 million in Q2 2019.